Results 61 to 70 of about 2,000 (177)

Supplemental Material - Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA

, 2023
Supplemental Material for Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA by Nicolas Margot, Nina Pennetzdorfer, Vidula Naik, Martin Rhee, and Christian Callebaut in Journal of Antiviral Therapy.
Nicolas Margot (420403), Nina Pennetzdorfer (17643043), Vidula Naik (17643046), Christian Callebaut (2276590), Martin Rhee (13378385)   +4 more
core   +1 more source

Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial

Open Forum Infectious Diseases
Background Injectable cabotegravir (CAB)/rilpivirine (RPV) is the only combination long-acting (LA) antiretroviral regimen approved for HIV. RPV may not be effective among individuals with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance,
Monica Gandhi, Lucas Hill, Janet Grochowski, Alexander Nelson, Catherine A Koss, Francis Mayorga-Munoz, Jon J. Oskarsson, Mary Shiels, Ann K. Avery, Laura Bamford, Jillian Baron, W. Short, Corrilynn O. Hileman   +12 more
semanticscholar   +1 more source

Binding of lenacapavir to HIV-1 CA.

Lenacapavir interacting with two CA molecules is represented based on a crystal structure (PDB ID: 6VKV) [70]. Two neighboring monomers are shown, their NTD and CTD domains have blue and green as well as orange and pink colors, respectively.
Gyula Hoffka (20904100), József Tőzsér (665273), Mohamed Mahdi (665270), János András Mótyán (3804706), Botond Lakatos (12478740)   +4 more
core   +1 more source

A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation

British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa, Cleodie C. Swire, Reya V. Shah, Bernadette Jenner, Rory H. McLean, Muhammad Shamsher Ahmed, Adrie Bekker, Julia Zöllner, Rachel K. Scott, Robert R. Bies, Sara K. Quinney, Dagan O. Lonsdale, Emma Forton Magavern, Catriona Waitt, Anita Banerjee   +14 more
wiley   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, Volume 27, Issue 9, Page 1421-1433, September 2026.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Long‐Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Long‐acting (LA) antiretroviral (ARV) medications represent a significant advancement in the HIV treatment and prevention field. LA ARVs help reduce daily pill burden and thus optimize adherence, which has translated into sustained virologic suppression in persons with HIV, prevention of HIV transmission among those at risk, and improved ...
Alexandra Dunbar, Natella Rakhmanina, Justin Unternaher, Peter L. Anderson, Kristina M. Brooks   +4 more
wiley   +1 more source

Bridging the Gap: The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention

Viruses
Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) demonstrates superior efficacy and persistence compared to daily oral PrEP. However, real-world implementation reveals that only 52.9% of prescribed individuals initiate treatment with their ...
Adrian Charles (AC) Demidont
doaj   +1 more source

Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods

Chirality, Volume 38, Issue 7, July 2026.
Chirality is crucial in drug development since both biological targets in the organism and the majority of pharmaceutical compounds are chiral. The synthesis and resolution of chiral compounds are critical steps while developing chiral drugs. Asymmetric synthesis and racemic resolution are the two most common methods for obtaining enantiopure drugs ...
Burcu Karayavuz, Cigdem Karaaslan Kirmizioglu   +1 more
wiley   +1 more source

Lenacapavir, el nuevo fármaco de acción prolongada contra el VIH-1

, 2023
Lenacapavir, un nuevo fármaco para el tratamiento de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) multirresistente, ha sido aprobado recientemente por la Agencia Europea del Medicamento (EMA) y por la agencia estadounidense del
Vidal Gil, Lorena
core  

577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir

Open Forum Infectious Diseases
Background Both islatravir (ISL), a nucleotide reverse transcriptase translocation inhibitor, and lenacapavir (LEN), a capsid inhibitor, have potent anti-HIV-1 activity and pharmacokinetic profiles permitting once-weekly oral dosing.
A. E. Colson, G. Crofoot, P. Ruane, M. Ramgopal, Alexandra W. Dretler, Ronald G. Nahass, G. Sinclair, M. Berhe, Fadi Shihadeh, Shan-Yu Liu, Stephanie O Klopfer, Sharline Madera, H. Dvory‐Sobol, Martin S Rhee, E. G. Rhee, Jared M. Baeten, Joseph J. Eron   +16 more
semanticscholar   +1 more source